Subgroups with high TMB and MSI scores are significantly enriched for mutant samples in CREBBP and/or EP300, especially in GEJ and gastric adenocarcinomas (>30%) and esophageal adenocarcinomas (16%), compared to TMB-Low and MSS groups (3–4%) (Figure 1). The gene discussed is CREBBP; the disease is esophageal adenocarcinoma.